01/03/2023
Interactive Response Technology (IRT) is an electronic system commonly used to manage investigational product (IP) supply and to randomize study participants while maintaining the blind, thus reducing bias and balancing enrollment into the treatment arms. Qualified site staff use the IRT to randomize doses according to protocol, and often the IRT will trigger an automatic refill when supply is low.
An investigator was recently issued a warning letter due to noncompliance with the IRT, which can impact the safety of the participants and the quality and integrity of the data. Per protocol, IP was to be administered according to hemoglobin levels and the IRT was to randomize the doses appropriately.
Observations that the FDA field investigator found were:
Coordinators ordered IP kits rather than using the IRT
IRT transactions to obtain randomized doses were not completed
IP was not administered per protocol
Participants missed multiple doses, sometimes with long periods of consecutive days
One participant who missed 43 doses was hospitalized to receive blood product
IP was administered when it should have been held
IP was held when it should have been administered
IP was administered at the full dose rather than the reduced dose
There was inadequate investigator oversight of the delegated site staff and study procedures evidenced by the investigator’s statement that they were not aware of the issues until a year after the multiple missed doses. The investigator also stated the nurses informed them about the lack of IP available at the site and the investigator managed the issue by texting the coordinator, while not indicating that any follow up for resolution or other oversight occurred. The FDA notes that the corrective action provided in the written response did not adequately describe how the investigator will comply with protocol and IRT procedures to prevent further issues. The neglect to use the IRT to generate randomized doses, lack of appropriate protocol required dose adjustments, and missed doses due to lack of IP supply adversely impacts participant safety and data quality.
Are you inspection ready or do you need help with inspection preparedness? Clinical Pathways can help! Contact us at info@clinicalpathwaysresearch.com
-The Clinical Pathways Team
Enjoy this blog? Please like, comment, and share with your contacts.